AnaptysBio, Inc. (ANAB) SEC Filings & Earnings Calls

GSK litigation risk

“On November 20, 2025, we filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that Tesaro has materially breached the GSK Agreement and that GSK, Tesaro's corporate parent, has tortiously interfered with the GSK Agreement.” · word for word

Concentration risk on Jemperli

“We derive substantially all of our revenues from GSK's commercialization of Jemperli .” · word for word

Keytruda biosimilar competition

“Keytruda® is expected to lose market exclusivity in Europe in 2031 following compound patent expiration.”

Royalty monetization cap

“As of June 30, 2026, Sagard has earned approximately $302.5 million in royalties and milestones.” · word for word

No employees

“As of June 30, 2026, we have no direct full-time or part-time employees.” · word for word

Potential loss of collaboration revenue or IP rights if litigation outcome unfavorable

“litigation over Collaboration and Exclusive License Agreement with Tesaro/GSK”

Spin-off execution risk

“Spin-off completed April 2026; CEO now consultant; key executives separated.”

Pre-revenue biotech with no approved products

“Net loss of $13.2M in 2025; company has no approved products.”

Sublease exposes company to master lease obligations if subtenant defaults.

“Company remains responsible for Basic Rent and Additional Rent under Master Lease.”

Concentration risk on two royalty streams (Jemperli and imsidolimab) with no diversified revenue base.

“Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda.” · word for word

Debt monetization of Jemperli royalties creates leverage; paydown dependent on GSK sales.

“Sagard will have accrued ~$275 million in royalties and sales milestones through Q1 2026 and anticipates paydown of the remaining ~$325 million non-recourse debt monetization by the end of Q2 2027.” · word for word

GSK lawsuit legal expense risk

“The increase is primarily due to an $8.3 million increase in legal expenses due to the GSK lawsuit” · word for word

Separation execution risk

“The recent separation of our business into two independent, publicly traded companies is subject to various risks and uncertainties” · word for word

Royalty revenue concentration risk

“Our royalty revenues depend on patent rights licensed to third parties, and if we or our licensees or collaborators are unable to obtain, maintain, and protect those patent rights, our royalty revenues and the value of our patent portfolio may be materially adversely affected.” · word for word

Tariff impact on royalty income

“Jemperli involves pharmaceutical ingredients that are partially sourced from outside of the United States, including China, the cost of which may increase due to additional tariff rates. Higher material costs may negatively impact our royalties.” · word for word

CFO is an independent contractor, not an employee, which may affect retention and alignment.

“Mr. Murphy will serve as an independent contractor. The Murphy Consulting Agreement provides for monthly consulting fees of $42,916.66.” · word for word

Spin-off execution and key person dependency

“Following the Spin-Off, our only executive officer will be Daniel Faga.” · word for word

Clinical trial failure risk

“As a pre-commercial biotechnology company, we do not believe Net Income is yet a reasonable metric to measure our financial performance.” · word for word

Spin-off execution risk: separation of biopharma operations may lead to operational disruption, loss of key personnel, and uncertain standalone viability.

“Spin-Off completed; board departures; executive transitions; consulting agreements for CEO.”

Loss of key executives (Mulroy, Loumeau) may impact operational continuity; termination of ATM program reduces financial flexibility.

“Separation agreements for Mulroy and Loumeau; termination of Sales Agreement.”

Spin-off execution risk; reliance on single drug (Jemperli) for royalty revenue; GSK peak sales guidance may not materialize.

“Spin-off of biopharma operations; Jemperli royalty stream dependent on GSK's commercial success.”

Separation execution risk; preliminary financial data subject to audit adjustment.

“Preliminary financial information is an estimate subject to completion of audit.”

Dependence on GSK collaboration and Vanda license for royalty income.

“Potential substantial Jemperli royalties from GSK; potential imsidolimab royalties from Vanda.”

Litigation risk with potential loss of collaboration revenue or reversion of rights

“AnaptysBio brings this action to obtain a declaration that it is entitled to that remedy and obtain all other appropriate relief” · word for word

Counterclaim by Tesaro/GSK adds uncertainty

“Tesaro and GSK publicly filed their complaint against AnaptysBio claiming that AnaptysBio has breached the Collaboration Agreement” · word for word

Material contract dispute with partner Tesaro/GSK over Jemperli exclusivity and commercial efforts; countersuit filed; trial scheduled July 2026

“Tesaro initiated lawsuit against AnaptysBio on Nov. 20, 2025, claiming breach; AnaptysBio's complaint alleges Tesaro violated exclusivity and failed to use commercially reasonable efforts for Jemperli.”

Potential loss of Jemperli royalty stream if contract terminated or settlement unfavorable

“Forward-looking statements mention potential termination of the Collaboration Agreement and return of Jemperli to the company.”

Potential dilution from future equity offerings if needed.

“Buyback program may be offset by future capital needs.”

Dependence on GSK's Jemperli commercialization and royalty payments.

“Significant royalties on global net sales of Jemperli, which is marketed by GSK.”

Clinical trial risks for pipeline candidates (rosnilimab, ANB033, ANB101).

“Phase 2 data in UC with rosnilimab; Phase 1b for ANB033 in celiac disease.”

Proposed separation may not be completed on terms or timeline

“The proposed separation of our business into two independent, publicly traded companies is subject to various risks and uncertainties and may not be completed on the terms or timeline currently contemplated, if at all.” · word for word

Clinical trial failure risk for rosnilimab in ulcerative colitis

“even though we showed positive data for rosnilimab in our Phase 2b clinical trial in rheumatoid arthritis, data from rosnilimab's ongoing Phase 2 clinical trial in ulcerative colitis may not be positive.” · word for word

Dependence on GSK collaboration for revenue

“Our existing collaboration with GSK and other collaborations are important to our business, and other future collaborations may also be important to us. If we are unable to maintain the GSK collaboration, or if this collaboration is not successful, our business could be adversely affected.” · word for word

Clinical-stage biotech with no approved products; pipeline risk remains

“clinical-stage biotechnology company” · word for word

Dependence on GSK for Jemperli royalties and milestones

“GSK Jemperli Financial Collaboration” · word for word